Mikhail Blagosklonny’s Take On Rejuvenation of Immunity Using an Anti-Aging Drug and Understanding Oncology

Aging was until recently considered to be a decline due to the high accumulation of casual molecular damage that is unpreventable. A hyperfunction theory described aging as the continuation of the growth process spurred on by signal paths like TOR (Target of Rapamycin). Rapamycin has been identified as a useful component in the prevention of diseases as well as treating the aging process in human beings. When offered in the correct doses, rapalogs and rapamycin are used in extending the healthy lifespan of human beings. This theory had been disapproved by anonymous peer-reviewers as well as opponents in the past.


Recent studies have established that a rapamycin analog, Evirolimus (RAD001), generally improves the immunity of aging persons. This news made headlines as researchers are on the brink of finding a drug that will be capable of delaying the effects associated with aging and generally improve the health of adults in advanced ages. Nir Barzilai summarizes that this new discovery has set the stage for finding a drug that will improve every pending thing about the aging process. At the moment, both human beings and animals die as a result of diseases related to age, due to the aging process. When the aging process is slowed down, calorie restriction and rapamycin will be capable of delaying all age-related diseases like cancer. In the study of anti-oxidants and free radicals, gerontologists stumbled upon metformin and rapamycin, which are anti-aging drugs. Intensive studies on rapamycin and other anti-aging drugs are ongoing in order to find conclusive results on their anti-aging properties.

Understanding Oncology Via Mikhail Blagosklonny

Mikhail Blagosklonny is a renowned scientist who majors in the studies of both cancer and the aging process. He is an Oncology professor at the Roswell Park Cancer Institute. He holds an MD (Internal Medicine) as well as an Experimental Medicine and Cardiology Ph.D. from the First Pavlov State Medical University, St. Petersburg. Dr. Blagosklonny is a great professor who is interested in the areas of cancer, anti-aging drugs as well as targeted cancer therapies in nature in order to prevent healthy cells from harm.Mikhail Blagosklonny, Oncotarget’s editor-in-chief, came up with a hypothesis that touches on TOR signaling playing a major role in the aging process as well as cancer. He proposes the use of rapamycin, a drug that is popularly used in cancer treatment. Dr. Blagosklonny suggested that there is a possible breakthrough treatment that can treat lie extension. Mikhail Blagosklonny is held in high regard as he is a passionate rapamycin advocate. His research touches on molecular and cellular biology in his clinical investigations. His investigations mainly include drug resistance in normal cells, ontogenesis, signal transduction, tumor suppressors, apoptosis, mitosis, anticancer therapeutics and cell cycle.

Mikhail Blagosklonny and Oncology

Dr. Blagosklonny is widely known for his huge passion in the oncology field. He holds a strong belief that both cancer and aging processes can be controlled. He suggested the use of rapamycin in cancer treatment as he believes that it can cure cancer. His huge passion and contributions in this field have made him become one of the top Oncology researchers on the planet.

How Mikhail Blagosklonny has been instrumental in the success of Oncotarget

The transformative state of medical research

For several years, there has been a big problem with the quality of medication, especially in the area of research. Most physicians and researchers rely on the information which is available, but in the field of medicine, the information is always scanty. For this reason, the qualities of therapies have always been compromised. Diseases like cancer have new developments every day and relying on a single resource would be detrimental to the health of the general public.

Transformation to a better condition

Currently, several journals have been availed to help with the treatment processes. Oncotarget is an organization that helps researchers and physicians to get free journals on how to handle different forms of therapies. The organization ensures that the journals are availed without any pay so that the parties that would find them useful can get their required resources. Through this move, the researchers who could were not in a position to purchase their resources found some relief. Equally, the quality of medication has been improved as most doctors have sufficient information about the types of cancers before the patients present them.

The contribution of Mikhail Blagosklonny

Mikhail Blagosklonny has had long years of studying aging and cancer. He has established different treatment options that can be used in the processes. Because of his understanding and influence in the field of therapy, he has helped several researchers to come up with ways in which they can solve their puzzles. Currently, Mikhail Blagosklonny has shaped the operations of Oncotarget as he does most of the journals by himself. Having developed a team of workers who are all scientists, the group does their research to confirm the information indicated in different journals.

Salience of Oncotarget on quality

Several researchers have developed an interest in the field of medicine and research I cancer therapy. The fact that there are insufficient resources to guide their research work has reduced the influence which they have had on the field. In most cases, the interested researchers are students who lack sufficient funds to help in their course. Since Oncotarget offers free journals, research has been made easier, and the quality has been improved.

Eric Lefkofsky Offers Tempus to Help Fight Breast Cancer

Eric Lefkofsky is the founder of Groupon. But Eric Lefkofsky is behind the cancer-fighting startup Tempus too. Eric Lefkofsky is offering it to doctors at the University of Chicago. This way they can get data that will help them to treat the breast cancer patients in a much better way.Tempus is Chicago-based. It has recently announced its partnership with the University of Chicago Medicine Thursday. Tempus will provide molecular sequencing along with analysis. This will be provided to UChicago’s specialists in breast cancer. This will allow them to create customized treatment plans for their patients.

Tempus will be analyzing data from nearly 1,000 breast cancer patients. This will help the doctors as well researchers to uncover patterns that can help to predict how patients are going to respond to any specific treatment.Over time, such kind of data analysis will help in providing better treatment along with improved patient outcomes.

Eric Lefkofsky realized that even though breast cancer is one of the most common cancers, it has relatively little data on the millions of patients who are battling or have battled this disease. Hence many physicians are forced to make treatment decisions with no help coming from highly specific genetic information. Had this information been available, these physicians could have made better informed and targeted decisions. Hence partnering with Tempus with regard to this initiative is going to be really exciting. Physicians are quite eager to support all its efforts towards building the largest possible clinically annotated molecular data set that will be specific to breast cancer.

Tempus will be using machine learning along with genomic sequencing in order to help doctors in making real-time treatment decisions. This startup is headquartered in Chicago, where other ventures like Groupon, Lightbank as well as Drivin are also located.UChicago happens to be the latest in multiple partnerships being landed by Tempus in recent months. Other partnerships include working with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, besides the Mayo Clinic, as well as Rush University Medical Center. Others include Penn Medicine, besides the University of Michigan for fighting cancer.